Editas Medicine
E661988
Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Editas Medicine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7392984 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Editas Medicine Context triple: [George Church, coFounded, Editas Medicine]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Editas Medicine Target entity description: Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| aimsToTreat |
hematologic diseases
ⓘ
inherited retinal diseases ⓘ serious genetic diseases ⓘ |
| collaboratedWith |
Allergan
ⓘ
Bristol Myers Squibb ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| develops |
gene-editing therapies
ⓘ
genome editing medicines ⓘ |
| focusesOn |
CRISPR-based gene-editing therapies
ⓘ
ex vivo gene editing ⓘ genetic medicines ⓘ in vivo gene editing ⓘ |
| foundedBy |
David Liu
ⓘ
David R. Liu ⓘ Feng Zhang ⓘ Feng Zhang (scientist) ⓘ
linked to:
Feng Zhang
George Church ⓘ George M. Church ⓘ
linked to:
George Church
J. Keith Joung ⓘ
linked to:
Keith Joung
Jennifer A. Doudna ⓘ
linked to:
Jennifer Doudna
Jennifer Doudna ⓘ Keith Joung ⓘ Rodolphe Barrangou ⓘ |
| foundingYear | 2013 ⓘ |
| hasClinicalTrials |
CRISPR-based therapies for blood disorders
ⓘ
CRISPR-based therapies for inherited retinal diseases ⓘ |
| hasIntellectualProperty | CRISPR gene-editing patents ⓘ |
| hasPipeline |
beta-thalassemia programs
ⓘ
inherited retinal disease programs ⓘ sickle cell disease programs ⓘ |
| hasWebsite | https://www.editasmedicine.com ⓘ |
| headquartersLocation |
Cambridge, Massachusetts, United States
ⓘ
linked to:
Cambridge, Massachusetts
|
| industry | biotechnology ⓘ |
| languageOfWorkOrName | English ⓘ |
| legalForm | corporation ⓘ |
| locatedInTimeZone | Eastern Time Zone ⓘ |
| researchArea |
genetic engineering
ⓘ
genome editing ⓘ hematologic malignancies ⓘ ocular diseases ⓘ |
| stockExchange | NASDAQ ⓘ |
| tickerSymbol | EDIT ⓘ |
| usesTechnology |
CRISPR-Cas12a
ⓘ
linked to:
Cpf1 (Cas12a)
CRISPR-Cas9 ⓘ
linked to:
CRISPR-Cas systems
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Editas Medicine Description of subject: Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.